Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  ISIS Pharmaceuticals, Inc.    ISIS

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

ISIS Pharmaceuticals, Inc. : ISIS, YHOO, MU and INTC added to Nasdaq Active Stock Watch List at EPR

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/25/2013 | 03:05pm CET

New York, NY -- (ACCESSWIRE) --06/25/2013-- Equity Profile Report initiates a NASDAQ Active Stock Watch List adding Isis Pharmaceuticals, Inc. (NASDAQ:ISIS), Yahoo! Inc. (NASDAQ:YHOO), Micron Technology Inc. (NASDAQ:MU) and Intel Corporation (NASDAQ:INTC)

Isis Pharmaceuticals, Inc. (NASDAQ:ISIS) a leading company in antisense drug discovery and development finished their previous session (+29.24%) on 9,784,879 shares traded. They recently announced that the data they received from the PHASE 2 study of ISIS-APOCIIIRx in patients with high triglycerides and type 2 diabetes was very positive. They are currently us (+275.93%) from its recent 52-week low which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll.

To find out what other Investors are saying about Isis Pharmaceuticals, Inc. (NASDAQ:ISIS)

Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=ISIS&SubId=AW

Yahoo! Inc. (NASDAQ:YHOO) ?a company that provides search, content and communication tools via the web and mobile devices around the world finished their previous session (-4.47%) on 37,007,539. They recently announced that they have completed their acquisition of Tumblr, who are one of the fastest growing media networks in the world. This acquisition is expected to grow Yahoo?s audience by more than one billion monthly visitors. This news has prompted Equity Profile Report to add Yahoo! Inc. (NASDAQ:YHOO) to their NASDAQ Active Stock Watch List and Investor Poll.

To find out what other Investors are saying about Yahoo! Inc. (NASDAQ:YHOO)

Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=YHOO&SubId=AW

Also mentioned in Equity Profile Report?s Active Stock Watch List and Investor Poll was: Micron Technology Inc. (NASDAQ:MU), Intel Corporation (NASDAQ:INTC), ARM Holdings plc (NASDAQ:ARMH) and NetApp, Inc. (NASDAQ:NTAP)

To see what other investors are saying about: MU, INTC, ARMH and NTAP

Click here: http://www.equityprofilereport.com/PR.aspx?stock=MU-INTC-ARMH-NTAP&SubId=AW

EquityProfileReport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals EquityProfileReport.com is often aware of several large investor awareness campaigns being deployed. Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here:http://www.EquityProfileReport.com

Disclosure: EquityProfileReport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit EquityProfileReport.com website, for complete risks and disclosures.

Contact Info:

Equity Profile Report
editor@EquityProfileReport.com


© Accesswire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ISIS PHARMACEUTICALS, INC.
12/01 OTONOMY : Appoints Kathie M. Bishop, Ph.D., as Chief Scientific Officer
11/17 IONIS PHARMACEUTICALS : Reports Financial Results and Highlights for Third Quart..
11/17 IONIS PHARMACEUTICALS : 1,000 Shares of Stock are Sold by Ionis Pharmaceuticals ..
11/15 ISIS PHARMACEUTICALS : Ionis Pharmaceuticals Reports Positive Clinical Data from..
11/10 IONIS PHARMACEUTICALS : Reports Positive Phase 2 Data for IONIS-FXI Rx in Patien..
11/09 IONIS PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDIT..
11/09 IONIS PHARMACEUTICALS, INC. (NASDAQ : IONS) Files An 8-K Reports Financial Resul..
11/09 IONIS PHARMACEUTICALS INC : Results of Operations and Financial Condition, Finan..
11/09 IONIS PHARMACEUTICALS : misses Street 3Q forecasts
11/08 IONIS PHARMACEUTICALS INC. : (IONS) is Trading Lower on Unusual Volume for Novem..
More news
Sector news : Biotechnology & Medical Research - NEC
12/03DJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 Pharma execs weigh in on possible changes under Trump
11/30 ACTELION : Rejecting J&J could leave Actelion with 'lot of explaining to do'
11/28 Actelion's ambitious independent-minded CEO will drive up takeover price
11/26DJWHAT'S NEWS : Business & Finance -- WSJ
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
2015 Game Plan For The Week - Cramer's Mad Money (12/18/15)
2015 PREMARKET BIOTECH DIGEST : Portola's Milestone, Shkreli Resigns, BioMarin DMD Dr..
2015 Isis Pharma has had enough, name changed to Ionis Pharmaceuticals
2015 Bear Afoot? No Recession Needed For A Possible Sighting
2015 PREMARKET BIOTECH DIGEST : Gilead's Upside, Shire-Baxalta Deal, ARIAD Lowers Gui..
Advertisement
Financials ($)
Sales 2016 275 M
EBIT 2016 -101 M
Net income 2016 -130 M
Finance 2016 40,6 M
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales 2016 18,8x
EV / Sales 2017 15,5x
Capitalization 5 212 M
More Financials
Chart ISIS PHARMACEUTICALS, INC.
Duration : Period :
ISIS Pharmaceuticals, Inc. Technical Analysis Chart | ISIS | US4643301090 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus HOLD
Number of Analysts 13
Average target price 43,6 $
Spread / Average Target 1,4%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Stanley T. Crooke Chairman, President & Chief Executive Officer
B. Lynne Parshall Chief Operating Officer & Director
Elizabeth L. Hougen Chief Financial Officer & Senior VP-Finance
Joseph H. Wender Independent Director
Frederick T. Muto Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ISIS PHARMACEUTICALS, ..-6.12%5 212
INCYTE CORPORATION-5.68%19 219
QUINTILES IMS HOLDINGS..11.90%18 225
CELLTRION, INC.--.--%9 953
SEATTLE GENETICS, INC.44.41%9 442
LONZA GROUP AG11.34%9 247
More Results